Last reviewed · How we verify
PF-07104091 + PF-07220060 + letrozole dose expansion — Competitive Intelligence Brief
phase 1
Live · refreshed every 30 min
Target snapshot
PF-07104091 + PF-07220060 + letrozole dose expansion (pf-07104091-pf-07220060-letrozole-dose-expansion) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PF-07104091 + PF-07220060 + letrozole dose expansion TARGET | pf-07104091-pf-07220060-letrozole-dose-expansion | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PF-07104091 + PF-07220060 + letrozole dose expansion CI watch — RSS
- PF-07104091 + PF-07220060 + letrozole dose expansion CI watch — Atom
- PF-07104091 + PF-07220060 + letrozole dose expansion CI watch — JSON
- PF-07104091 + PF-07220060 + letrozole dose expansion alone — RSS
Cite this brief
Drug Landscape (2026). PF-07104091 + PF-07220060 + letrozole dose expansion — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07104091-pf-07220060-letrozole-dose-expansion. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab